Holen Sie sich die Stockscreener-App
1.24
0.80%
-0.01
Schlusskurs vom Vortag:
$1.25
Offen:
$1.25
24-Stunden-Volumen:
908.00K
Relative Volume:
0.48
Marktkapitalisierung:
$154.38M
Einnahmen:
$1.55M
Nettoeinkommen (Verlust:
$-63.06M
KGV:
-1.558
EPS:
-0.7959
Netto-Cashflow:
$-49.45M
1W Leistung:
-4.62%
1M Leistung:
-11.43%
6M Leistung:
-40.38%
1J Leistung:
-36.08%
1-Tages-Spanne:
$1.23
$1.27
1-Wochen-Bereich:
$1.20
$1.36
52-Wochen-Spanne:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Firmenname
Milestone Pharmaceuticals Inc
Sektor
Branche
Telefon
(514) 336-0444
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.24 | 154.38M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-15 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-09-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-06-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-03 | Eingeleitet | Cowen | Outperform |
| 2019-06-03 | Eingeleitet | Jefferies | Buy |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Milestone Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIST) - TradingView
MIST Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - TMX Newsfile
Milestone Pharmaceuticals (MIST) Investor update Summary - Quartr
Milestone Pharmaceuticals Inc (MIST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Milestone Pharmaceuticals Inc - TradingKey
Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Milestone Pharmaceuticals Inc (MIST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Milestone Pharmaceuticals Inc (MIST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Milestone Pharmaceuticals Inc (MIST) Institutional Confidence - TradingKey
Milestone Pharmaceuticals Inc (MIST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Milestone Pharmaceuticals Inc (MIST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Milestone Pharmaceuticals Inc (MIST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Milestone Pharmaceuticals Shareholders Approve Governance and Compensation Measures - The Globe and Mail
Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC - Stock Titan
Milestone (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike - Stock Titan
Milestone Pharmaceuticals (MIST) awards director 77,000 stock options - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 - Stock Titan
Director at Milestone Pharmaceuticals (MIST) receives 77,000 stock options at $1.22 - Stock Titan
Milestone Pharmaceuticals (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives grant of 77,000 stock options - Stock Titan
Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST) - Seeking Alpha
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets) - Newswire Canada
Milestone Pharmaceuticals: Taking The Long View (NASDAQ:MIST) - Seeking Alpha
Eli Lilly scores a first in major pharma milestone - thestreet.com
Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org - PR Newswire
Wockhardt's Zaynich wins US FDA approval, marking milestone in antibiotic innovation - Business Today
Milestone (MIST) Q1 2026 Earnings Transcript - The Globe and Mail
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - PR Newswire
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
[EFFECT] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
H.C. Wainwright Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals (MIST) Slides 7.24% as Selling Pressure Builds—Key Support at $1.34 in FocusOBV Divergence - thelegaladvocate.com
Milestone Pharmaceuticals Q1 earnings call highlights - MSN
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Milestone reports Q1 results, highlights initial CARDAMYST sales - MSN
Milestone Pharmaceuticals Q1 2026 earnings preview - MSN
Milestone outlines ~2-year phase III AFib-RVR timeline as CARDAMYST launch reaches ~600 prescriptions - MSN
Milestone Pharmaceuticals (MIST) reports Q1 loss, lags revenue estimates - MSN
RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership - Stock Titan
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability - Yahoo Finance
Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near? - simplywall.st
MIST Maintained by Wells Fargo -- Price Target Lowered to $7.00 - GuruFocus
Milestone Pharmaceuticals Is Maintained at Overweight by Wells Fargo - Moomoo
Wells Fargo & Company Issues Pessimistic Forecast for Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price - MarketBeat
Milestone Pharmaceuticals Inc.Common Shares (NQ: MIST - FinancialContent
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
NASDAQ fireside chat: Milestone talks cardiovascular drugs on May 19 - Stock Titan
Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):